Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Codexis, Inc.NASDAQ: CDXS
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables declines year over year
Q1 FY2026 accounts payables of $312K fell 84.9% year over year, ahead of the -297.9% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 1.8% of revenue in FY2025, down 2.5 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -84.9% holds above the trailing-twelve-month pace of -297.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.29M) USD
- Year-over-year change
- +49.9%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.29M) | +49.9% |
| FY2024 | 2024-12-31 | (2.57M) | -212.2% |
| FY2023 | 2023-12-31 | 2.29M | +1004.8% |
| FY2022 | 2022-12-31 | 207K | -22.8% |
| FY2021 | 2021-12-31 | 268K | — |
Accounts Payables vs competitors
How CDXS compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -297.9% is the lowest of 9, against a peer median of -21.0%.
- Accounts payables amounts to 3.9% of revenue for CDXS, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.72M USD | -188.7% | — | 12.0% | |
| LTM Mar 2026 | $3.51M USD | +170.1% | -40.6% | 10.2% | |
| LTM Mar 2026 | $3.04M USD | -297.9% | — | 3.9% | |
| LTM Mar 2026 | $1.72M USD | +28.5% | — | — | |
| LTM Mar 2026 | $662K USD | -192.7% | — | 20.9% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $337K USD | -70.4% | +107.3% | 17.3% |
| LTM Mar 2026 | $215K USD | +111.0% | — | 0.7% | |
| LTM Mar 2026 | $133K USD | -95.3% | — | 4.5% | |
| LTM Mar 2026 | $92K USD | +109.7% | -48.0% | 0.3% | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding CDXS) | — | -21.0% | -40.6% | 7.3% | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Depreciation & Amortization | 5.95M | 10.25M | 9.92M | 4.95M | 5.25M |
| Deferred Income Tax | (2.89M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.59M | 14.53M | 9.97M | 13.09M | 9.62M |
| Change in Working Capital | (7.62M) | 21.57M | (18.22M) | (12.02M) | 6.42M |
| Accounts Receivables | (15.57M) | (3.23M) | 20.25M | 1.25M | 8.51M |
| Inventory | (196K) | (869K) | (656K) | 886K | (19K) |
| Accounts Payables | 268K | 207K | 2.29M | (2.57M) | (1.29M) |
| Other Working Capital | 7.88M | 25.46M | (40.1M) | (11.59M) | (784K) |
| Other Non-Cash Items | (19K) | (1.48M) | 21.93M | 9.85M | 3.31M |
| Operating Cash Flow | (14.27M) | 11.28M | (52.64M) | (49.41M) | (19.38M) |
| Capital Expenditures | (13.83M) | (8.31M) | (4.42M) | (4.31M) | (4.47M) |
| Acquisitions (Net) | 36K | 29K | 751K | 87K | 5K |
| Purchases of Investments | (7.63M) | (5.3M) | (1.19M) | (90.24M) | (57.16M) |
| Sales of Investments | (36K) | (29K) | 440K | 37.47M | 85.13M |
| Other Investing Activities | 36K | 29K | (440K) | 0 | 0 |
| Investing Cash Flow | (21.42M) | (13.58M) | (4.86M) | (56.98M) | 23.5M |
| Debt Repayment | 0 | 0 | 0 | 29.52M | 9.89M |
| Common Stock Issued | 4.97M | 913K | 8.65M | 31.32M | 18.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.21M) | (1.49M) | (485K) | (318K) | 0 |
| Financing Cash Flow | 3.77M | (575K) | 8.17M | 60.52M | 27.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (31.92M) | (2.87M) | (49.33M) | (45.87M) | 32.05M |
| Free Cash Flow | (28.1M) | 2.98M | (57.06M) | (53.72M) | (23.85M) |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.